Home / Market News / $ALNY
fiscal.ai Corporate Catalyst Impact 75/100 ● neutral

Multiple Analysts Adjust Alnylam Pharmaceuticals Price Targets Following Q3 Earnings

Oct 31, 2026, 1:04 PM UTC · Primary ticker $ALNY

Following its Q3 earnings, Alnylam Pharmaceuticals saw multiple analyst price target reductions, despite some maintaining 'Buy' ratings. This reflects investor concern over the TRITON-CM trial design and demand growth, indicating a potential revaluation of the company's future prospects.

Multiple analysts revised their price targets for Alnylam Pharmaceuticals downwards after the company's third-quarter earnings release. This widespread reduction, even from firms maintaining 'Buy' ratings, signals a collective reassessment of ALNY's valuation by the investment community. The primary drivers for this negative sentiment are concerns surrounding the TRITON-CM trial design and slower-than-expected demand growth. This development is significant for current ALNY shareholders as it suggests potential downward pressure on the stock in the short term, reflecting a more cautious outlook on the company's future revenue and pipeline success. For traders, this presents a potential short opportunity or a signal to re-evaluate long positions, as the market digests these revised expectations.

$ALNY negative Analyst price target reductions and valuation reassessment
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.